Additionally, Kumar et al. reported significant differences in the progression and overall progression-free survival in a larger study of more than 501 myeloma patients with a median cut-off level of syndecan-1 of 158 ng/ml. The gene discussed is SDC1; the disease is plasma cell myeloma.